Final Thoughts on S1P Receptor Modulators in Multiple Sclerosis


Bruce Cree, MD, PhD, MAS, presents his final thoughts for clinicians on the safety, efficacy, and tolerability of sphinogine-1-phospate (S1P) receptor modulators in the treatment of multiple sclerosis (MS).


Bruce Cree, MD, PhD, MAS: S1P [sphinogine-1-phospate] receptor modulators, as a class, do offer a safe, well-tolerated, and highly efficacious therapeutic option that is an oral therapy for our patients, and is, generally speaking, fairly easily reversible in the sense that the medications can be discontinued. They, especially the next generation ones, have a relatively short half-life. So, the therapeutic effects of these medications can resolve fairly quickly after discontinuation. For patients who are not looking at the long-term commitment that anti-CD20 monoclonal antibodies have, these medications, as a class, do offer patients a combination of high degrees of efficacy, excellent safety profiles, and really fantastic tolerability for treatment of relapsing forms of MS, including active secondary progressive MS.

Transcript edited for clarity.

Related Videos
Monica Verduzco-Gutierrez, MD
Michael Levy, MD, PhD
Michael Levy, MD, PhD
Tarun Singhal, MD, MBBS
Jaime Imitol, MD
Eoin P. Flanagan, MB, BCh
© 2024 MJH Life Sciences

All rights reserved.